###begin article-title 0
A Newly Identified Insertion Mutation in the Thyroid Hormone Receptor-beta Gene in a Korean Family with Generalized Thyroid Hormone Resistance
###end article-title 0
###begin p 1
###xml 394 398 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 546 550 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 648 652 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 1017 1021 1014 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 1105 1113 <span type="species:ncbi:9606">patients</span>
Thyroid hormone resistance syndrome (RTH) is a rare disorder and is characterized by elevated levels of circulating free thyroid hormones, inappropriate secretion of thyroid stimulating hormone (TSH), and reduced peripheral tissue response to thyroid hormone. 90% of RTH subjects, when studied at the level of the gene, have been found to harbor mutations in the thyroid hormone receptor-beta (THRB) gene. These affected individuals have been shown to possess a variety of missense mutations, resulting from changes in a single nucleotide in the THRB gene that corresponds to amino acid alternation. However, insertion or deletion mutations in the THRB gene sequence are quite rare, and have been observed in only a very few cases. In this study, we describe two such cases, in which two members of the same family were determined to harbor an insertion mutation in exon 10, and had also been diagnosed with generalized RTH. This insertion mutation, specifically the insertion of a cytosine at nucleotide 1358 of the THRB gene, is, to the best of our knowledge, the first such mutation reported among RTH patients in Korea.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 386 390 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 521 522 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 613 617 610 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 624 625 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
The syndromes of resistance to thyroid hormone (RTH) are characterized by reduced clinical and biochemical manifestations of thyroid hormone action relative to the circulating hormone levels (1). Since Refetoff et al. initially identified this syndrome in 1967 (2), over 1,000 cases have been identified (3). RTH has been associated with mutations in the thyroid hormone receptor-beta (THRB) gene. These mutations have, been identified in RTH patients from 300 families, and 122 different mutations have been discovered (3). In 10% of cases of thyroid hormone hyposensitivity, no mutations can be detected in the THRB gene (4).
###end p 3
###begin p 4
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 510 514 510 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 380 388 <span type="species:ncbi:9606">patients</span>
Only three cases (5, 6) of RTH have been reported in the Korean literature. All of these reported cases of RTH have been determined to be the result of point mutations in different regions of the THRB gene. One of these cases presented as pituitary RTH (5), and the other two presented as generalized RTH (5, 6). However, no insertion mutations have, been described in Korean RTH patients. Therefore, this report represents the first observation of generalized RTH associated with an insertion mutation in the THRB gene in Korea, found in two individuals from the same family. These results were confirmed via sequence analysis.
###end p 4
###begin title 5
CASE REPORT
###end title 5
###begin p 6
###xml 1922 1926 1922 1926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 2218 2222 2218 2222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 2343 2350 2343 2350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 2655 2659 2655 2659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 2753 2759 2753 2759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 9 14 <span type="species:ncbi:9606">woman</span>
###xml 567 574 <span type="species:ncbi:9606">patient</span>
###xml 747 754 <span type="species:ncbi:9606">patient</span>
###xml 1939 1946 <span type="species:ncbi:9606">patient</span>
###xml 2044 2051 <span type="species:ncbi:9606">patient</span>
A Korean woman initially noticed an enlargement in her thyroid gland at the age of 43. The thyroid function test revealed elevated free thyroxine (T4) with nonsuppressed thyroid stimulating hormone (TSH). She exhibited none of the signs and symptoms of thyrotoxicosis, which include wasting, agitation, and tachycardia despite high serum levels of thyroid hormone. Ultrasonography revealed a diffuse goiter with a nodule in each lobe. Due to the findings of elevated serum thyroid hormone levels, coupled with increased thyroid radioiodide uptake (46% at 24 hr), the patient was presumed to have primary hyperthyroidism. Therefore, methimazole therapy was administered, and antithyroid drug treatment continued for several months. However, as the patient's TSH levels remained slightly elevated, and free T4 and triiodothyronine (T3) were still in excess of upper normal levels after antithyroid drug treatment, RTH was suspected, and so the methimazole treatment was discontinued. TSH-secreting adenoma was ruled out on the basis of the following findings: clinical phenotype without manifestations of thyrotoxicosis, a negative magnetic resonance imaging (MRI) of the pituitary gland, and the level of the -subunit of TSH being within normal range. Her serum level of free T4 was 751.6 pM/L (normal range, 121-322.8), total T3 was 0.058 nM/L (normal range, 0.012-0.034), and TSH was 1.49 mU/L (normal range, 0.17-4.05). Thyroid hormone and TSH levels were measured via radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Thyroid autoantibodies, including anti-thyroid peroxidase antibody, anti-thyroglobulin antibody, and TSH receptor antibody, were all found to be negative. Basal metabolic rate, serum cholesterol, and serum sex hormone binding globulin levels were all normal. She exhibited resistance to thyroid hormone in peripheral and pituitary tissues. A polymerase chain reaction (PCR) sequencing of the THRB gene of the patient was subsequently conducted. Genomic DNA was isolated from the peripheral blood leukocytes of the patient, in accordance with the standard protocols. PCR amplification (PTC-200, MJ Research, Watertown, MS, U.S.A.) was conducted on seven coding exons (exon 4 to 10) of the THRB gene. The PCR products were then employed in a direct sequence analysis, using primers identical to those used for PCR (Table 2), with a BigDye Terminator system, version 3.0 (ABI Systems, Forester, CA, U.S.A.). The sequences were analyzed using the computational software, ABI PRISM Sequence Analysis, version 3.7 (Applied Biosystems, Forster City, CA, U.S.A.). In the sequence analysis, we discovered a mutation in exon 10 of the THRB gene, specifically, cytosine inserted at position 1358/1359 (1358_1359insC, Leu454PhefsX11) (Fig. 1).
###end p 6
###begin p 7
###xml 32 39 <span type="species:ncbi:9606">patient</span>
###xml 90 97 <span type="species:ncbi:9606">patient</span>
###xml 516 523 <span type="species:ncbi:9606">patient</span>
During the period in which this patient was still being evaluated with regard to RTH, the patient also underwent a subtotal thyroidectomy at another hospital, in which the right lobe was completely removed and the left lobe was partially removed. This procedure was necessitated due to the discovery of solid nodules in the thyroid, which, according to the results of fine needle aspiration cytology, appeared to suggest a follicular neoplasm. The actual pathologic finding of the tumor was benign adenoma. When the patient revisited our hospital, she had shown to manifest postprocedural hypothyroidism and hypoparathyroidism. She was then placed on thyroxine, calcium, and vitamin D. The thyroxine dosage was repeatedly adjusted on the basis of her serum free T4 levels, pre-surgical TSH level, clinical manifestations of thyroid hormone excess or deficiency, and tissue indices of thyroid hormone action, including basal metabolic rate or sex hormone-binding globulin levels.
###end p 7
###begin p 8
###xml 363 366 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">99m</sup>
###xml 782 792 782 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1B, C</xref>
###xml 901 905 901 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 997 1004 997 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 20 28 <span type="species:ncbi:9606">children</span>
The patient had two children. Her 18-yr-old son and 12-yr-old daughter also visited our clinic in order to have their thyroid functions evaluated. Her son was found to have elevated thyroid hormone levels, but was clinically euthyroid. His serum free T4 level was 583 pM/L (normal range, 121-321.8), and his TSH level was 6.71 mU/L (normal range, 0.17-4.05). The 99mTechnetium thyroid scan revealed diffuse enlargement of the thyroid glands, increased uptake, and a warm nodule. Ultrasonography revealed a diffuse goiter with a solid nodule in the left lobe, which, upon fine needle aspiration cytology, was suggestive of benign adenoma. Sera from the mother and her son evidenced identical abnormalities, with regard to the insertion mutation in nucleotide 1,358/1,359 in exon 10 (Fig. 1B, C). Her daughter, however, exhibited no abnormalities, with regard to both her thyroid function tests and her THRB gene sequence. Detailed clinical information of the index case and of her son are shown in Table 1.
###end p 8
###begin title 9
DISCUSSION
###end title 9
###begin p 10
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 947 948 947 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 938 945 <span type="species:ncbi:9606">patient</span>
RTH is an inherited condition induced by defects that reduce the responsiveness of the target tissues to thyroid hormone (1). The incidence of RTH is probably approximately 1 case per 40,000 live births (7). The clinical presentation of RTH is also known to be highly variable. Whereas most individuals are clinically euthyroid, some individuals with RTH may appear to be overtly hypothyroid, while others may appear thyrotoxic. Furthermore, the same subject with RTH can manifest signs and symptoms of hypothyroidism in one tissue, while in another tissue, the findings may be suggestive of thyrotoxicosis. RTH patients that appear eumetabolic or hypothyroid are considered to be suffering from generalized RTH (GRTH), and those with a hypermetabolic clinical presentation are generally referred to as having pituitary RTH (3). Finally, the occurrence of isolated peripheral tissue resistance to thyroid hormone was reported in a single patient (8).
###end p 10
###begin p 11
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRA</italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 440 441 419 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 453 458 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRA1</italic>
###xml 463 468 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB1</italic>
###xml 497 502 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRA1</italic>
###xml 565 570 544 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB1</italic>
###xml 623 628 602 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB2</italic>
###xml 710 715 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB3</italic>
###xml 782 783 761 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 785 787 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 893 897 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 950 954 929 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRA</italic>
###xml 961 962 940 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 964 965 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 972 976 951 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 1004 1006 983 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1434 1438 1413 1417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 1518 1520 1497 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1521 1523 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
Thyroid hormone receptors (TRs) are ligand-dependent transcription factors, which mediate the biological activities of T3. TRs are encoded for by the THRA and THRB genes, which are located on chromosomes 3 and 17, respectively (3). The alternative splicing of the primary transcripts results in the formation of four T3-binding proteins (beta1, beta2, beta3, and alpha1), as well as two proteins that do not bind to T3 (alpha2 and alpha3) (9). Although THRA1 and THRB1 are ubiquitously expressed, THRA1 is expressed primarily in the heart, bone, and brain, whereas THRB1 is more abundant in the liver, kidney, and thyroid. THRB2 expression is limited to the pituitary, hypothalamus, retina, and inner ear, and THRB3 expression has been detected principally in the heart and kidney (7, 11). 90% of RTH subjects, when studied at the level of the gene, have been found to harbor mutations in the THRB gene. No mutations have so far been detected in the THRA gene (3, 9). The THRB gene consists of 10 exons (12); the aforementioned mutations are located in the last 4 exons, which code for the hinge region and the ligand-binding domain of the receptor. The majority of these mutations result in a reduction in T3-binding and/or an impairment in transactivation. The majority of the previously described mutations are diverse missense mutations that induce single amino acid substitutions. However, insertion or deletion mutations of the THRB gene sequence are quite rare, and have been observed in only a very few cases (13-16).
###end p 11
###begin p 12
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 498 503 <span type="species:ncbi:9606">woman</span>
###xml 546 551 <span type="species:ncbi:9606">woman</span>
To the best of our knowledge, this is the second report in the literature to describe a cytosine insertion mutation at this position in the THRB gene. Although this insertion mutation is definitely the first such case in the Korean literature, a similar case was previously reported by Takeda et al. (16). They described this mutation in the thyroid hormone receptor, which was identified as a cytosine insertion at position 1644, resulting in a frameshift mutation (Leu454PhefsX11) in a 74-yr old woman presenting with GRTH. A screening of this woman's family members resulted in the detection of similar biochemical abnormalities in two other relatives. These appeared to be mutations identical to those described in this paper.
###end p 12
###begin p 13
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 269 274 <span type="species:ncbi:9606">child</span>
###xml 347 355 <span type="species:ncbi:9606">Patients</span>
Familial occurrence of RTH has been documented in approximately 75% of cases (3). Inheritance is autosomal dominant (3). Transmission was clearly recessive in only one family (2, 17). Consanguinity in a family with dominant inheritance of RTH has produced a homozygous child with severe resistance to the hormone who died at the age of 7 yr (18). Patients exhibiting a frameshift mutation from codon 454 to 463 can be considered to have GRTH, and appear to transmit the condition in an autosomal dominant manner, according to two reports (the present case, 16).
###end p 13
###begin p 14
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 477 481 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">THRB</italic>
###xml 1097 1099 1097 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 132 140 <span type="species:ncbi:9606">patients</span>
Another interesting characteristic of our two cases involves the thyroid nodules found prior to surgery. Thyroid enlargement in RTH patients tends to be diffuse, whereas nodular changes and gross asymmetry are more common features of recurrent goiters after surgery (1). Taniyama et al. (19) has reported only one case of GRTH that was accompanied by a toxic multinodular goiter and thyroid microcarcinoma. A molecular examination of this case revealed a R429Q mutation in the THRB gene. This is one of the mutations that is usually associated with a pituitary resistance phenotype. In our case, the solid nodule in the index case upon fine needle aspiration cytology was suggestive of follicular neoplasm. The postsurgical pathologic examination confirmed the existence of benign adenoma within the thyroid gland and found no evidence of malignancy. The etiology of nodular goiters has yet to be clearly elucidated, but continuous growth stimulation by thyrotrophic substances including TSH, thyroid growth stimulating immunoglobulin, and IGF-1, is believed to be involved in cell proliferation (20). Continuous stimulation by excess TSH may be a causative factor in some cases of RTH.
###end p 14
###begin p 15
###xml 218 226 <span type="species:ncbi:9606">patients</span>
In this study, we have described a 1358-1359 insC mutation in exon 10 occurring in two members of the same family, both of whom were diagnosed with generalized RTH. This mutation has not been observed in any other RTH patients in Korea, but has been postulated to be the cause of RTH in the family described in this study.
###end p 15
###begin article-title 16
The syndromes of resistance to thyroid hormone
###end article-title 16
###begin article-title 17
Familial syndrome combining deaf-mutism, stippled epiphyses, goiter, and abnormally high PBI: Possible target organ refractoriness to thyroid hormone
###end article-title 17
###begin article-title 18
Resistance to thyroid hormones
###end article-title 18
###begin article-title 19
Thyrotropin receptor mutations in thyroid diseases
###end article-title 19
###begin article-title 20
A case of syndrome of resistance to thyroid hormone associated with mutation (M313T) in thyroid hormone receptor beta gene
###end article-title 20
###begin article-title 21
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Mutations in thyroid hormone receptor-beta associated with patients with generalized resistance and pituitary resistance to thyroid hormone
###end article-title 21
###begin article-title 22
Follow-up of newborns with elevated screening T4 concentrations
###end article-title 22
###begin article-title 23
Partial peripheral resistance to thyroid hormone
###end article-title 23
###begin article-title 24
Thyroid hormone receptor mutations and disease: beyond thyroid hormone resistance
###end article-title 24
###begin article-title 25
Identification of a thyroid hormone receptor that is pituitary-specific
###end article-title 25
###begin article-title 26
Cloning and characterization of two novel thyroid hormone receptor beta isoforms
###end article-title 26
###begin article-title 27
###xml 23 28 <span type="species:ncbi:9606">human</span>
Structural analysis of human thyroid normone receptor beta gene
###end article-title 27
###begin article-title 28
Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain
###end article-title 28
###begin article-title 29
Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene
###end article-title 29
###begin article-title 30
###xml 70 77 <span type="species:ncbi:9606">patient</span>
A novel mutation (1653insC) in the thyroid hormone receptor beta in a patient resistant to thyroid hormone
###end article-title 30
###begin article-title 31
Rapid localization of mutations in the thyroid hormone receptor-beta gene by denaturing gradient gel electrophoresis in 18 families with thyroid hormone resistance
###end article-title 31
###begin article-title 32
Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone
###end article-title 32
###begin article-title 33
Recessive inheritance of thyroid hormone resistance caused by complete deletion of the protein-coding region of the thyroid hormone receptor-beta gene
###end article-title 33
###begin article-title 34
###xml 31 38 <span type="species:ncbi:9606">patient</span>
Toxic multinodular goiter in a patient with generalized resistance to thyroid hormone who harbours the R429Q mutation in the thyroid hormone receptor beta gene
###end article-title 34
###begin article-title 35
Growth factors and goitrogenesis
###end article-title 35
###begin p 36
###xml 60 66 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TH- RB</italic>
###xml 89 90 86 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 105 106 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 169 170 166 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 80 87 <span type="species:ncbi:9606">patient</span>
The sequence analysis of the thyroid hormone receptor-beta (TH- RB) gene in the patient (B) and her son (C) shows an insertion of a C at position 1358/1359 in exon 10. (A) Normal control.
###end p 36
###begin p 37
Clinical and biochemical parameters of the index case and her son with thyroid hormone resistance syndrome
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 52 53 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
*Following administration of 125-150 microg/day of T4 over 6 months.
###end p 38
###begin p 39
Tg Ab, anti-thyroglobulin antibodies; TPO Ab, anti-thyroid peroxidase antibodies; TSHR Ab, TSH receptor antibodies; BMR, basal metabolic rate; SHBG, sex hormone binding globulin; pos, positive; neg, negative.
###end p 39
###begin p 40
The sequences of primers used in amplification of thyroid hormone receptor-beta gene
###end p 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 78 84 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*The primer sets were designed using Primer3 cgi.0.6 (Steve and Helen, 2000). daggerThe sequences were retrieved from Genebank database: NT_022517.17 (NCBI, Bethesda, MD, USA; ).
###end p 41

